Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Waldschmidt, D. [1 ]
El-Khoueir, A. B. [2 ]
Kim, R. D. [3 ]
Harris, W. P. [4 ]
Sung, M. W. [5 ]
Iqbal, S. [2 ]
Zhang, A. [6 ]
Nakajima, K. [6 ]
Galle, P. R. [7 ]
机构：
[1] Univ Klin Koln, Klin Gastroenterol & Hepatol, Cologne, Germany
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Tisch Canc Inst Mt Sinai, New York, NY USA
[6] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[7] Univ Med Ctr Mainz, Mainz, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
153
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [41] Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
    Slater, Susanna
    Cunningham, David
    LANCET, 2023, 401 (10391): : 1826 - 1827
  • [42] Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
    Chan, S. L.
    Finn, R. S.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A. B.
    Bautista, O.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study
    Finn, Richard S.
    Blumenschein, George R.
    Tolcher, Anthony W.
    Leong, Stephen
    Boix, Oliver
    Diefenbach, Konstanze
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [44] Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE)
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Kim, Hyung-Don
    Ryu, Min-Hee
    Kang, Beodeul
    Chon, Hong Jae
    Hong, Jung Yong
    Lim, Ho Yeong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Insights into the future of first-line advanced hepatocellular carcinoma treatment
    Wong, Jeffrey Sum Lung
    Wong, Carmen Chak-Lui
    Sun, Frances Sze Kei
    Yau, Thomas
    LANCET ONCOLOGY, 2025, 26 (02): : 152 - 153
  • [46] Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
    Feng, Maple Ye
    Chan, Landon L.
    Chan, Stephen Lam
    CURRENT ONCOLOGY, 2022, 29 (08) : 5489 - 5507
  • [47] KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
    Dummer, R.
    Shapira, R.
    Pigozzo, J.
    Ascierto, P. A.
    Marqueste, C. Gaudy
    Portnoy, D.
    Del Vecchio, M.
    Bar-Sela, G.
    Cohen, J. E.
    Di Giacomo, A. M.
    Ribas, A.
    Dutriaux, C.
    Belli, C.
    Cohen, G.
    Dokhan, R.
    Jing, N.
    Lal, R.
    Krepler, C.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2024, 35 : S717 - S718
  • [48] Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Merle, Philippe
    Kudo, Masatoshi
    Bouattour, Mohamed
    Lim, Ho-Yeong
    Breder, Valeriy Vladimirovich
    Edeline, Julien
    Chao, Yee
    Ogasawara, Sadahisa
    Yau, Thomas
    Garrido, Marcelo
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Ebbinghaus, Scot
    Chen, Erluo
    Siegel, Abby B.
    Zhu, Andrew X.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
    Finn, Richard S.
    Chan, Stephen L.
    Zhu, Andrew X.
    Knox, Jennifer J.
    Cheng, Ann-Lii
    Siegel, Abby B.
    Bautista, Oliver
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
    Finn, R. S.
    Chan, S. L.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A. B.
    Bautista, O.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345